Nifty
:
8378.00
Sensex
:
28824.28
-282.25 (-3.26%)
-991.31 (-3.32%)
Nifty
Sensex
:
:
8378.00
28824.28
-282.25 (-3.26%)
-991.31 (-3.32%)

Cipla Ltd.

Pharmaceuticals & Drugs

Rating :
70/99

BSE: 500087 | NSE: CIPLA

NSE BSE
407.65
27-Mar-2020
  • Open
  • High
  • Low
  • Previous Close
  •  393.00
  •  411.00
  •  391.95
  •  386.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  6471292
  •  26086.94
  •  586.00
  •  355.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 32,930.68
  • 19.75
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 36,628.10
  • 0.73%
  • 2.06

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 36.68%
  • 4.04%
  • 16.02%
  • FII
  • DII
  • Others
  • 20.3%
  • 20.44%
  • 2.52%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.81
  • 7.60
  • 4.36

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.33
  • 5.82
  • 2.99

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.62
  • 5.08
  • 15.09

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 30.14
  • 34.38
  • 34.03

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.56
  • 3.49
  • 3.10

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.77
  • 16.92
  • 14.99

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Net Sales
4371
4008
9%
4396
4012
10%
3989
3939
1%
4404
3698
19%
Expenses
3613
3300
9%
3486
3310
5%
3084
3213
-4%
3443
3141
10%
EBITDA
758
708
7%
910
702
30%
905
726
25%
961
557
73%
EBIDTM
17%
18%
21%
18%
23%
18%
22%
15%
Other Income
72
79
-8%
101
133
-24%
78
170
-54%
95
40
138%
Interest
46
44
4%
46
44
4%
52
35
49%
45
35
27%
Depreciation
278
293
-5%
283
282
0%
268
241
11%
510
285
79%
PBT
506
449
13%
681
509
34%
663
620
7%
501
199
152%
Tax
153
126
22%
201
142
41%
192
174
11%
128
46
177%
PAT
354
323
9%
480
366
31%
471
447
5%
374
153
144%
PATM
8%
8%
11%
9%
12%
11%
8%
4%
EPS
4.35
4.12
6%
5.85
4.68
25%
5.93
5.60
6%
4.56
2.22
105%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
17,159.78
16,362.41
15,155.71
14,394.29
13,594.89
11,345.44
10,173.39
8,279.33
7,020.71
6,323.84
5,359.52
Net Sales Growth
9.60%
7.96%
5.29%
5.88%
19.83%
11.52%
22.88%
17.93%
11.02%
17.99%
 
Cost Of Goods Sold
5,788.29
5,784.49
5,438.42
5,317.12
5,089.86
4,270.63
3,874.83
2,952.61
2,739.30
2,775.18
2,452.98
Gross Profit
11,371.49
10,577.92
9,717.29
9,077.17
8,505.03
7,074.81
6,298.56
5,326.72
4,281.41
3,548.66
2,906.54
GP Margin
66.27%
64.65%
64.12%
63.06%
62.56%
62.36%
61.91%
64.34%
60.98%
56.12%
54.23%
Total Expenditure
13,626.26
13,494.26
12,702.32
11,918.50
11,115.22
9,183.74
8,040.34
6,081.48
5,361.86
4,954.60
4,286.56
Power & Fuel Cost
-
335.11
298.82
251.73
245.92
228.28
218.63
233.12
235.35
198.55
92.15
% Of Sales
-
2.05%
1.97%
1.75%
1.81%
2.01%
2.15%
2.82%
3.35%
3.14%
1.72%
Employee Cost
-
2,856.53
2,690.10
2,633.82
2,434.01
1,967.72
1,542.96
1,036.02
772.50
565.59
289.59
% Of Sales
-
17.46%
17.75%
18.30%
17.90%
17.34%
15.17%
12.51%
11.00%
8.94%
5.40%
Manufacturing Exp.
-
1,284.94
1,220.67
1,192.77
1,596.79
737.11
644.42
541.58
583.18
627.94
708.39
% Of Sales
-
7.85%
8.05%
8.29%
11.75%
6.50%
6.33%
6.54%
8.31%
9.93%
13.22%
General & Admin Exp.
-
1,096.50
1,002.43
868.31
845.89
743.46
638.08
496.81
369.85
288.71
231.05
% Of Sales
-
6.70%
6.61%
6.03%
6.22%
6.55%
6.27%
6.00%
5.27%
4.57%
4.31%
Selling & Distn. Exp.
-
1,281.29
1,082.90
1,009.21
818.76
738.87
680.32
466.22
467.61
386.67
326.48
% Of Sales
-
7.83%
7.15%
7.01%
6.02%
6.51%
6.69%
5.63%
6.66%
6.11%
6.09%
Miscellaneous Exp.
-
855.40
968.98
645.54
83.99
497.67
441.10
355.12
194.07
111.96
326.48
% Of Sales
-
5.23%
6.39%
4.48%
0.62%
4.39%
4.34%
4.29%
2.76%
1.77%
3.47%
EBITDA
3,533.52
2,868.15
2,453.39
2,475.79
2,479.67
2,161.70
2,133.05
2,197.85
1,658.85
1,369.24
1,072.96
EBITDA Margin
20.59%
17.53%
16.19%
17.20%
18.24%
19.05%
20.97%
26.55%
23.63%
21.65%
20.02%
Other Income
346.38
476.57
357.65
228.69
208.21
165.55
265.37
222.14
139.52
91.68
353.50
Interest
189.14
168.43
114.23
159.38
206.63
168.29
145.74
33.91
38.34
25.10
28.30
Depreciation
1,339.13
1,097.15
949.83
1,322.93
754.22
504.71
372.64
330.48
312.22
273.33
167.07
PBT
2,351.63
2,079.14
1,746.98
1,222.17
1,727.03
1,654.25
1,880.04
2,055.60
1,447.81
1,162.49
1,231.09
Tax
673.36
569.53
250.11
179.76
331.59
400.03
463.38
544.31
306.51
195.22
243.50
Tax Rate
28.63%
27.39%
14.98%
14.71%
19.20%
24.18%
24.65%
25.98%
21.17%
16.79%
18.36%
PAT
1,678.27
1,544.87
1,413.31
1,013.38
1,372.01
1,206.07
1,400.73
1,551.06
1,141.30
967.27
1,082.59
PAT before Minority Interest
1,727.33
1,509.61
1,419.35
1,042.41
1,395.44
1,254.22
1,416.66
1,551.06
1,141.30
967.27
1,082.59
Minority Interest
49.06
35.26
-6.04
-29.03
-23.43
-48.15
-15.93
0.00
0.00
0.00
0.00
PAT Margin
9.78%
9.44%
9.33%
7.04%
10.09%
10.63%
13.77%
18.73%
16.26%
15.30%
20.20%
PAT Growth
30.18%
9%
39%
-26%
14%
-14%
-10%
36%
18%
-11%
 
Unadjusted EPS
20.69
18.97
17.53
12.52
16.93
14.71
17.29
19.24
14.25
12.32
13.70

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
15,012.28
14,229.19
12,543.66
11,516.22
10,801.49
10,050.35
9,018.68
7,638.93
6,666.13
5,910.57
Share Capital
161.14
161.02
160.90
160.68
160.59
160.58
160.58
160.58
160.58
160.58
Total Reserves
14,794.10
14,001.91
12,320.74
11,266.12
10,557.74
9,868.12
8,858.10
7,478.35
6,505.55
5,749.99
Non-Current Liabilities
4,646.15
4,259.05
4,514.99
1,407.13
2,417.66
2,028.05
1,024.96
824.27
697.34
184.22
Secured Loans
47.70
0.00
0.00
207.00
287.09
317.44
0.00
0.00
15.00
0.41
Unsecured Loans
3,782.37
3,662.11
3,645.36
14.88
22.19
0.43
0.55
3.25
2.92
4.66
Long Term Provisions
121.41
137.92
140.52
144.68
1,783.17
1,368.64
713.87
557.78
466.30
0.00
Current Liabilities
3,771.51
3,832.22
3,388.91
7,776.05
3,881.13
2,563.58
2,277.63
1,413.19
1,698.54
2,525.63
Trade Payables
1,947.99
2,119.12
1,586.30
1,475.82
1,452.06
979.53
828.36
691.77
720.88
805.41
Other Current Liabilities
541.86
647.04
908.95
1,006.14
654.55
408.67
250.89
489.93
235.28
192.56
Short Term Borrowings
486.16
435.87
467.23
4,969.67
1,392.48
910.47
966.38
10.20
523.06
0.00
Short Term Provisions
795.50
630.19
426.43
324.42
382.04
264.91
232.00
221.29
219.32
1,527.66
Total Liabilities
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42
Net Block
9,546.51
9,949.14
9,508.16
9,368.32
6,829.64
6,496.47
3,609.97
3,215.49
3,094.18
2,011.17
Gross Block
13,665.08
12,960.01
11,370.70
10,167.62
9,561.55
8,676.27
5,317.52
4,626.35
4,240.55
2,897.26
Accumulated Depreciation
4,108.55
3,010.87
1,609.71
799.30
2,731.91
2,179.80
1,707.55
1,410.86
1,146.37
886.09
Non Current Assets
11,335.28
11,858.80
12,082.23
12,208.26
9,689.47
9,039.59
5,537.29
4,819.58
4,618.88
2,696.41
Capital Work in Progress
676.18
981.33
1,682.98
2,060.87
580.90
441.84
377.79
371.17
285.34
684.24
Non Current Investment
490.20
157.66
137.36
176.35
249.76
397.14
415.69
328.59
367.18
1.00
Long Term Loans & Adv.
455.57
514.96
543.67
426.18
1,860.78
1,552.40
978.96
865.38
841.20
0.00
Other Non Current Assets
166.82
255.71
210.06
176.54
168.39
151.74
154.88
38.95
30.98
0.00
Current Assets
12,426.63
10,814.10
8,803.56
8,841.23
7,591.29
5,651.97
6,783.98
5,056.81
4,443.13
5,924.01
Current Investments
2,125.79
1,102.21
837.39
582.34
390.02
311.43
2,116.75
940.52
223.59
245.41
Inventories
3,964.83
4,044.70
3,519.72
3,808.05
3,780.62
2,895.26
2,387.07
1,850.08
1,906.16
1,512.58
Sundry Debtors
4,150.72
3,102.45
2,582.17
2,356.27
1,997.72
1,638.89
1,668.84
1,553.58
1,490.82
1,566.63
Cash & Bank
618.81
965.61
638.27
871.40
564.26
175.76
143.01
90.46
95.97
62.06
Other Current Assets
1,566.48
480.20
418.17
437.05
858.67
630.63
468.31
622.17
726.59
2,537.33
Short Term Loans & Adv.
1,150.49
1,118.93
807.84
786.12
713.07
595.13
463.21
459.94
533.77
2,387.57
Net Current Assets
8,655.12
6,981.88
5,414.65
1,065.18
3,710.16
3,088.39
4,506.35
3,643.62
2,744.59
3,398.38
Total Assets
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,691.14
1,462.76
2,381.76
1,740.81
1,173.43
1,563.31
1,397.67
1,712.76
1,025.10
1,043.03
PBT
2,079.14
1,669.46
1,222.17
1,727.03
1,654.25
1,880.04
2,095.38
1,447.81
1,162.49
1,326.09
Adjustment
1,268.77
1,293.82
1,374.42
950.85
630.05
552.80
283.82
396.66
288.84
146.53
Changes in Working Capital
-1,063.54
-778.48
235.44
-429.38
-718.61
-561.26
-519.84
199.76
-162.03
-173.82
Cash after chg. in Working capital
2,284.37
2,184.80
2,832.03
2,248.50
1,565.69
1,871.58
1,859.36
2,044.23
1,289.30
1,298.80
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-593.23
-722.04
-450.27
-507.69
-392.26
-308.27
-461.69
-331.47
-264.20
-255.77
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,668.68
-854.01
-1,310.21
-4,522.63
-941.15
-1,249.86
-2,062.89
-965.10
-908.39
-562.75
Net Fixed Assets
-173.15
-509.84
-889.04
1,487.25
-534.38
-437.26
-692.52
-460.09
-601.86
-520.07
Net Investments
-1,239.74
-351.09
-30.10
164.99
-833.97
-985.31
-1,566.67
-464.50
-305.55
-183.78
Others
-255.79
6.92
-391.07
-6,174.87
427.20
172.71
196.30
-40.51
-0.98
141.10
Cash from Financing Activity
-348.72
-385.48
-1,325.68
3,104.06
164.78
-265.63
717.77
-753.17
-82.80
-471.61
Net Cash Inflow / Outflow
-326.26
223.27
-254.13
322.24
397.06
47.82
52.55
-5.51
33.91
8.67
Opening Cash & Equivalents
853.47
610.35
858.15
545.84
175.76
143.01
90.46
95.97
62.06
53.39
Closing Cash & Equivalent
508.36
853.46
610.35
858.15
564.26
175.76
143.01
90.46
95.97
62.06

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
185.62
175.92
155.15
142.23
133.38
124.79
112.21
95.03
82.91
73.50
ROA
6.50%
6.52%
4.97%
7.28%
7.85%
10.49%
13.97%
12.05%
10.94%
13.38%
ROE
10.37%
10.65%
8.72%
12.61%
12.10%
14.89%
18.64%
15.98%
15.40%
21.14%
ROCE
11.94%
10.20%
8.28%
13.24%
15.33%
19.05%
24.15%
19.96%
18.08%
24.22%
Fixed Asset Turnover
1.80
1.25
1.36
1.40
1.26
1.47
1.69
1.61
1.79
1.94
Receivable days
55.36
68.17
61.60
57.62
57.94
58.66
70.11
77.94
87.29
115.32
Inventory Days
61.13
90.71
91.41
100.43
106.36
93.68
92.19
96.16
97.61
98.17
Payable days
59.02
57.37
46.96
48.81
52.17
44.93
48.58
50.51
56.11
69.48
Cash Conversion Cycle
57.47
101.50
106.05
109.24
112.14
107.41
113.72
123.59
128.78
144.01
Total Debt/Equity
0.29
0.29
0.33
0.46
0.16
0.12
0.11
0.00
0.09
0.00
Interest Cover
13.34
15.61
8.67
9.36
10.83
13.90
62.79
38.76
47.31
47.86

Annual Reports:

FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011
FY 2010

News Update:


  • Cipla gets USFDA's nod for Esomeprazole for oral suspension
    26th Mar 2020, 12:20 PM

    Esomeprazole for Oral Suspension 10mg, 20mg and 40mg is AB-rated generic therapeutic equivalent version of AstraZeneca Pharmaceutical’s Nexium

    Read More
  • Cipla collaborates with CSIR-IICT
    18th Mar 2020, 10:36 AM

    The partnership is to work on development of anti- viral drugs to contain COVID-19

    Read More
  • Cipla receives warning letter from USFDA for Goa manufacturing facility
    26th Feb 2020, 09:46 AM

    The USFDA had conducted inspection from September 16, 2019 to September 27, 2019

    Read More
  • Cipla's arm inks pact for anti-psychotic drug
    11th Feb 2020, 10:34 AM

    The transaction allows Cipla Medpro to market and distribute the Medicine in South Africa and neighbouring countries

    Read More
  • Cipla acquires nutrition products’ portfolio from Wanbury
    10th Feb 2020, 09:25 AM

    The company has acquired 4 brands-CPink, CDense, Productiv and Folinine to further strengthen its presence in women’s health

    Read More
  • Cipla reports 6% rise in Q3 consolidated net profit
    6th Feb 2020, 10:25 AM

    Total consolidated income of the company increased by 8.74% at Rs 4,443.13 crore for Q3FY20

    Read More
  • Cipla gets EIR from USFDA for Invagen manufacturing facility
    28th Jan 2020, 09:26 AM

    The agency had conducted inspection from December 2, 2019 to December 6, 2019

    Read More
  • USFDA concludes cGMP inspection at Cipla’s Bangalore facility
    27th Jan 2020, 10:13 AM

    The inspection ended with 4 observations which were procedural in nature

    Read More
  • USFDA classifies inspection conducted at Cipla’s Goa facility as OAI
    23rd Jan 2020, 08:57 AM

    The Company will work closely with the agency to comprehensively address the observations received

    Read More
  • MUFG sells 2.10% shares in Cipla
    21st Jan 2020, 11:42 AM

    Prior to the sale, MUFG had 5.56 per cent shares in Cipla

    Read More
  • Cipla gets EIR from USFDA for Patalganga manufacturing facility
    20th Jan 2020, 09:36 AM

    USFDA had conducted inspection at Patalganga manufacturing facility from November 4, 2019 to November 13, 2019

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.